Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - Nemaura Medical Inc. | ex10x1.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
the Securities Exchange Act 1934
Date of Report (Date of earliest event reported): July 26, 2017
NEMAURA MEDICAL, INC.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
|
000-55283
|
46-5027260
|
|
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
Charnwood Building,
Holywell Park, Ashby Road,
Loughborough, Leicestershire
LE11 2PU
United Kingdom
|
N/A
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
Registrant’s telephone number, including area code:
|
00 44 1509 222912
|
|
|
(Former name or former address, if changed since last report)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 5.02. Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On July 26, 2017, the Board of Directors of the Registrant appointed Dr. Salim Natha as an independent director to serve on the Board of Directors and to chair the Compensation Committee.
Dr. Natha is an Ophthalmic Surgeon serving as a Consultant for Wrightington Wigan and Leigh NHS Foundation Trust Hospital, a position he has held since October 1, 2001. Dr. Natha graduated with honors from the University of Liverpool Medical School in 1992, and in 1997 became a Fellow of the Royal College of Ophthalmologists.
Dr. Natha shall receive compensation in the amount of £1,250 (approximately USD1620) for each quarter per calendar year for his service on the Board, inclusive of his committee service. In addition, the Registrant shall issue Dr. Natha stock options to purchase up to 20,000 shares of the Company’s common stock on an annual basis. The initial issuance of such stock options shall be awarded on the date of the Registrant’s first public offering at an exercise price equal to the public offering price for such offering.
There are no family relationships between Dr. Natha and any of the officers of director of the Company. Dr. Natha has not engaged in any related party transactions.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No.
|
Description
|
|
10.1
|
Form of Director Agreement
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Nemaura Medical, Inc. | |||
|
|
By:
|
/s/ Iain Anderson | |
| Name: | Iain Anderson | ||
| Title: | Chief Financial Officer | ||
Dated: August 1, 2017
Exhibit List
|
Exhibit No.
|
Description
|
|
10.1
|
Form of Director Agreement
|